UnitedHealthcare respiratory NAAT coverage update

Coverage Criteria

Not medically necessary — outpatient multiplex panels >=6 targets

Covered stance summary

Outpatient multiplex panels >=6 targets: Respiratory pathogen panel testing of six or more targets in an outpatient setting is considered unproven and not medically necessary due to insufficient evidence of efficacy for all indications.>=6 targets

Applies to outpatient setting only as stated.

Appropriate Use Considerations

Clinical guidance and evidence summarized from multiple societies and studies informing appropriate use

ASM guidance: ASM: multiplex molecular panel tests provide rapid multi-pathogen detection but lack robust outcome-based evidence; ASM identifies hematology/oncology, transplant, ICU, and pediatric patients with underlying illness as candidate groups for testing.

chunk 20

ATS guidance: ATS: suggests not performing routine outpatient nucleic acid–based testing for noninfluenza viral pathogens (conditional recommendation; very low quality evidence).

chunk 21

AMP/ASM/IDSA/PASCV consensus: Joint report: highlights variable performance by target and specimen type (positive agreement 16.7%–100%), concerns about distinguishing colonization from infection, and urges diagnostic stewardship to limit broad panel use in relatively healthy outpatients.

chunk 22

IDSA guidance: IDSA: recommend comprehensive respiratory pathogen testing for hospitalized/ICU patients to guide antimicrobial therapy and selective outpatient testing for patients with severe symptoms or those at high risk for complications (older adults, immunocompromised).

chunk 23

Evidence — Kaku et al.: Kaku et al. (prospective outpatient study, n=50): FilmArray detected pathogens but results were not reported to clinicians; small sample size and concurrent influenza epidemic limit generalizability and clinical utility conclusions.

chunk 18

Evidence — Green et al.: Green et al. (retrospective outpatient study, n=408): influenza-positive outpatients were less likely to receive antibiotics, but detection of noninfluenza viruses did not reduce antibiotic prescribing compared with negative tests; suggests targeted influenza testing may be sufficient in many outpatients.

chunk 19

This policy specifically addresses testing performed in the outpatient setting. UnitedHealthcare considers respiratory pathogen panel testing of six or more targets in an outpatient setting to be unproven and not medically necessary due to insufficient evidence of efficacy for all indications; this determination does not constitute a blanket prohibition on inpatient testing or applicable use in hospitalized patients where different considerations apply.

The American Thoracic Society (ATS) guidance cited in the policy suggests not performing routine outpatient nucleic acid–based testing of respiratory samples for noninfluenza viral pathogens in adults with suspected community-acquired pneumonia. This is a conditional recommendation based on very low–quality evidence, and supports more selective testing in the outpatient population rather than routine multiplex screening.

The policy rationale notes that outpatient panels with six or more targets are considered unproven and not medically necessary because current evidence does not demonstrate clear clinical benefit across outpatient indications. Joint society reports and studies highlight variable performance by target and specimen type, challenges distinguishing colonization from infection, and limited outcome data showing that broad panel results change management or improve patient outcomes in typical outpatient populations.

Consistent with the ATS position, the policy reflects a conditional recommendation against routine outpatient nucleic acid testing for noninfluenza viral pathogens. Given the very low quality of evidence, diagnostic stewardship and selective use for higher-risk patients are emphasized rather than routine multiplex testing for relatively healthy outpatients.

Covered Indications

When conventional tests fail or rapid pathogen identification is needed — consider more comprehensive testing such as mNGS

Consider more comprehensive testing when conventional methods are insufficient or rapid, broad pathogen detection is needed.

Indication for comprehensive testing (mNGS): When conventional tests fail to identify a pathogen or rapid, comprehensive pathogen identification is needed (for example in complex, atypical, or refractory respiratory infections), consider metagenomic next-generation sequencing (mNGS).

mNGS shows promise for pulmonary infections and immunocompromised individuals but clinical utility in outpatients is not established.

Evidence summary: mNGS demonstrates high diagnostic performance in pooled analyses (e.g., pooled sensitivity ~0.90 for pulmonary infections) and may be particularly useful in immunocompromised patients; limitations include heterogeneity across studies and lack of outpatient-specific utility data.

chunk 8

Hospitalized patients (especially ICU), hematology/oncology, transplant patients, and pediatric patients with underlying illness

Coding and Panel Details

Proprietary/multiplex panel codes (listed group)HCPCS

0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.

CPT / Proprietary respiratory multiplex codesmixed

0556U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0563U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
0564U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
87632	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87633	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.

Added CPT CodesCPT

0556U	CPT code added (description not provided in this excerpt)
0563U	CPT code added (description not provided in this excerpt)
0564U	CPT code added (description not provided in this excerpt)

Panel target count threshold — >= 6 targets

Threshold>= 6 targets (panels of six or more targets)

Policy contextRespiratory pathogen panel testing of six or more targets in an outpatient setting is considered unproven and not medically necessary.

ScopeApplies to outpatient setting only as stated in the Coverage Rationale.

Positive agreement range reported across targets and specimen types

Reported range16.7% to 100% positive agreement reported across targets and specimen types

Negative agreement

Provider Actions & Billing Notes

Denial Risk

Outpatient multiplex panels (≥6 targets) — Denial risk; prefer targeted testing

Outpatient respiratory pathogen panels that detect six or more targets are considered not medically necessary. Providers should prefer targeted testing (influenza, RSV, SARS-CoV-2) when clinically appropriate.

Outpatient panels with ≥6 targets: Not medically necessary for outpatient use — denial risk.
When clinically indicated, order targeted tests for influenza, RSV, and SARS-CoV-2 instead of broad multiplex panels.
Check member-specific benefits and federal/state/contractual requirements before ordering; this policy is informational and may not override plan or regulatory mandates.

Prior Authorization

Verify coverage & prior authorization for new CPT codes

New CPT codes for expanded respiratory NAAT panels have been added; providers must verify coverage and prior authorization (PA) requirements with the member's plan before ordering. Inclusion of a code in this policy does not guarantee coverage or payment.

Ordering Requirements

Step Therapy

Order targeted respiratory tests first in outpatients

In outpatient settings, order targeted molecular tests for influenza, RSV, and SARS‑CoV‑2 preferentially when clinically appropriate rather than broad multiplex panels.

Targeted testing may better guide antiviral therapy and reduce unnecessary multiplex testing.
Document why targeted testing is inadequate if ordering a broad panel for an outpatient.

Documentation Required

Check benefit plan coverage and UnitedHealthcare reimbursement policies before ordering

Providers must check federal, state, and contractual benefit plan coverage and UnitedHealthcare reimbursement policies before ordering multiplex respiratory testing; this policy is informational and does not supersede plan terms.

Verify member-specific benefits and prior authorization requirements prior to testing.
When conflicts exist, federal/state/contractual requirements govern coverage determinations.

Not Covered

UnitedHealthcare considers respiratory pathogen panel testing of six or more targets in the outpatient setting to be not medically necessary / unproven. Joint society statements and evidence cited in the policy note variable assay performance (positive agreement reported as low as 16.7% for some targets), potential difficulty distinguishing colonization from infection, and insufficient data that broad outpatient panels improve clinical outcomes, supporting the decision to not cover such outpatient panels.

Routine multiplex molecular testing for noninfluenza viruses in relatively healthy outpatients is questioned by professional guidance and may be considered not necessary. The ATS guidance specifically advises against routine outpatient nucleic acid–based testing for noninfluenza viral pathogens, and joint society reports recommend diagnostic stewardship to limit broad-panel use in outpatient populations unlikely to benefit.

Definitions

Multiplex RT-PCR definition

DefinitionAssay that identifies predefined microbial genetic material (RNA or DNA) in respiratory specimens and reports multiple analytes as detected or not detected using reverse transcription–PCR or other nucleic acid amplification methods.

Typical useUsed in multiplex respiratory panels that report multiple viral and sometimes bacterial targets from a single specimen.

Relation to codesSeveral proprietary and CPT codes in this policy describe multiplex RT-PCR panels (e.g., 87632, 87633, and listed proprietary codes).

Metagenomic next-generation sequencing (mNGS) definition

DefinitionComprehensive sequencing approach that detects genetic material from all organisms in a sample to identify possible pathogens by comparing nucleic acid sequences to reference databases.

Background

Molecular assays for respiratory pathogens include multiplex reverse transcription–polymerase chain reaction (multiplex RT‑PCR) panels, which detect predefined viral and bacterial targets and report each analyte as detected or not detected, as well as metagenomic next‑generation sequencing (mNGS), a comprehensive sequencing approach that can detect genetic material from a wide range of organisms. While multiplex RT‑PCR panels provide rapid multi‑pathogen detection, mNGS can identify atypical or unexpected organisms; however, detection alone does not necessarily indicate viable or causative infection, and clinical utility—particularly for broad panels in outpatients—remains limited.

Frequency Limits

Frequency limits — not specified in this partial document

Frequency limitsNot specified in this partial document.

Policy noteThe document excerpt does not provide repeat testing intervals or quantitative frequency limits for respiratory panels.

Action for providersRefer to full policy or benefit plan documents for any plan-specific frequency rules or prior authorization requirements.

Frequency limits — placeholder

GuidanceIf frequency limits are required by a plan, providers should check the member-specific benefit plan and UnitedHealthcare reimbursement policies; this excerpt contains no explicit limits.

OpenPayer

Respiratory Pathogen Nucleic Acid Detection Testing (for New Jersey Only)